学术搜索 · AI 审稿 · LaTeX 协作

Daniel Gerlach

ORCID：0000-0001-9338-3765

发表论文 227 篇 · 总被引 9252 次 · h-index 33

代表论文

Table S12 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules (2026)
Figure S8 from SOS1 Inhibition Enhances the Efficacy of KRAS<sup>G12C</sup> Inhibitors and Delays Resistance in Lung Adenocarcinoma (2026)
Table S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules (2026)
Figure S4 from SOS1 Inhibition Enhances the Efficacy of KRAS<sup>G12C</sup> Inhibitors and Delays Resistance in Lung Adenocarcinoma (2026)
Figure S18 from SOS1 Inhibition Enhances the Efficacy of KRAS<sup>G12C</sup> Inhibitors and Delays Resistance in Lung Adenocarcinoma (2026)
Figure S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules (2026)